FDA urges end to widely used uterine fibroid treatment

04/23/2014 | New York Times (tiered subscription model), The

The FDA has urged physicians to stop performing power morcellation to address uterine fibroids in women because the procedure may spread malignant tissue. The procedure is used to break up uterine fibroids and in surgeries to remove the uterus, but it may also spread cancerous tissue in cases where the women have previously undetected sarcomas, a situation that may occur in as many as 1 in 350 women who undergo hysterectomy or uterine fibroid removal.

View Full Article in:

New York Times (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN